The pharmaceutical industry in China has been expanding in recent years as the government strives to invent its own drugs and brands. However, the prevalence of counterfeit and generic drugs still remains a significant IP issue. The patent system needs further development before it will be able to properly protect patent holders.
At an event co-sponsored by Foley & Lardner LLP and Asia Law & Practice, “China's Innovation Boom: Doing Business and Achieving Growth in China”, Foley attorneys addressed effective strategies to obtain, protect, and enforce IPR.
By Yi ZhouRayYin & Partners P.R.C. LawyersAs the dispute of Foxconn Versus BYD Company Limited is dramatically escalating from a civil case to a criminal…
By Meloday DangRouse & Co InternationalItalian confectioner Ferrero Rocher filed a lawsuit against Montresor (Zhangjiagang) Food, a Chinese competitor,…
By Manisha Singh NairLexOrbis Intellectual Property PracticeCopyright is a right given by the law to the creators of literary, dramatic, musical and artistic…
How do the Leading Lawyer nominations reflect the evolution of the legal system in China? China Law & Practice takes a closer look at the results, and speaks to the nominees about their areas of expertise. Hear from the experts what the future holds for China law.